| ID | 1345 |
| Name of the vaccine | PCV13i |
| Microbe | Bacteria |
| Disease name | Pneumococcal |
| Name of bacteria | Streptococcus pneumoniae |
| Type of vaccine | Conjugate |
| Nucleic acid content | DNA |
| Age | 6 weeks and older |
| Description of the vaccine | 13-Valent Pneumococcal polysaccharide conjugate vaccine (CRM197,TT) |
| Name of the manufacturer | CanSino Biologics Inc. |
| Name of the manufacturing country | China |
| Year of manufacture | 2023 |
| Clinical Phase status | Clinical - Phase 3 |
| Bacterial strain | Gram-positive, facultative anaerobic bacteria. |
| Efficacy | NA |
| Vaccine formulation | NA |
| Dosage | At 2 and months of age: Four doses
7 to 11 months: Three doses
12 to 23 months: Two doses
2 to 5 years: One dose |
| Mechanism of action | NA |
| Route of administration | Intramuscular |
| Indications | NA |
| Export | NA |
| Approval | NA |
| Adjuvant | NA |
| Repurposing | For Streptococcal and bacterial infections |
| Side effects of vaccine | NA |
| Post vaccination | NA |
| Dose type | Both |
| Interspecies transfer | NA |
| PubMed identifier | NA |
| Clinical trial number | NCT04841369 |
| Reference | NA |
| Other name | NA |
| Additional Links | NA
|